Relapsed/Refractory Large B Cell Lymphoma

Oncology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Allogene Therapeutics
Allogene TherapeuticsSOUTH SAN FRANCISCO, CA
2 programs
1
1
ALLO-647Phase 21 trial
ALLO-501Phase 11 trial
Active Trials
NCT03939026CompletedEst. Jan 2025
NCT05714345TerminatedEst. Oct 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allogene TherapeuticsALLO-647
Allogene TherapeuticsALLO-501

Clinical Trials (2)

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Start: Nov 2023Est. completion: Oct 2024
Phase 2Terminated

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Start: May 2019Est. completion: Jan 2025
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space